Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

Foghorn Therapeutics (Nasdaq: FHTX) announces participation in the William Blair Biotech Focus Conference 2021 with CEO Adrian Gottschalk on July 15 at 9:00 a.m. ET.

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX) announces participation in the William Blair Biotech Focus Conference 2021 with CEO Adrian Gottschalk on July 15 at 9:00 a.m. ET. The conference will focus on next-generation small molecules in oncology. A live webcast of the panel can be accessed through the company’s website under the ‘Events & Presentations’ section. Foghorn is dedicated to developing a novel class of medicines targeting genetically determined dependencies in the chromatin regulatory system, with ongoing projects in oncology.

Argus Session date unavailable

+0.98% session move Open Argus

Details

News Market Reaction – FHTX

The recorded move for FHTX in the trading session of this news was +0.98%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

Panel Details:
Title: Next Generation Small Molecules in Oncology
Panel date and time: Thursday, July 15, 9:00 a.m. ET

A live webcast of the panel can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavalié, Foghorn Therapeutics
fcavalie@foghorntx.com

Gregory Kelley, Ogilvy
gregory.kelley@ogilvy.com

Investor Relations Contact:

Allan Reine, Foghorn Therapeutics
areine@foghorntx.com

Hans Vitzthun, LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Foghorn Therapeutics participating in the William Blair Biotech Focus Conference?

Foghorn Therapeutics will participate in the William Blair Biotech Focus Conference on July 15, 2021, at 9:00 a.m. ET.

Who is the CEO of Foghorn Therapeutics?

The CEO of Foghorn Therapeutics is Adrian Gottschalk.

Where can I watch the Foghorn Therapeutics conference panel?

The panel can be watched live on the Foghorn Therapeutics website under the 'Events & Presentations' section.

What is Foghorn Therapeutics known for?

Foghorn Therapeutics is known for discovering and developing a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system.

What topics will be covered at the Foghorn Therapeutics panel?

The panel will cover next-generation small molecules in oncology.